主要从事基于生物质谱技术的蛋白质组学及蛋白质翻译后修饰组学在肿瘤精准医疗中的研究。已发表 SCI 论文 40 余篇，包括以第一（含共一）作者及通讯（含共通讯）身份在 Cell、Nat Commun.、Arthritis Rheumatol.、CancerLett.、Genom Proteom Bioninf.、Mol. Cell Proteomics.、Sci China Life Sci.、Acta Pharmacol Sin.等期刊发表论文20余篇，研究工作入选《中国 2020 年度重要医学进展》和《2020 年上海科技进步报告》，并受到中央电视台、人民日报、EurekAlert 等国内外媒体广泛报道。作为项目主持人主持国家自然科学基金面上项目（2项）、青年基金（1项），以及上海市科委“青年科技英才扬帆计划”基金（1项）；参与申请授权专利4项，并实现商品转化1项;参与编写并已出版的蛋白质组学著作2部（《蛋白质组学与精准医学》、《创新药物研发经纬》）。

代表性文章：

1.      Xu J#, Zhang C#, Wang X#, ZhaiL#, Ma Y#, Mao Y, Qian K, Sun C, Liu Z, Jiang S, Wang M, Feng L, Zhao L, Liu P,Wang B, Zhao X, Xie H, Yang X, Zhao L, Chang Y, Jia J, Wang X, Zhang Y, Wang Y,Yang Y, Wu Z, Yang L, Liu B, Zhao T, Ren S, Sun A, Zhao Y, Ying W, Wang F, WangG, Zhang Y, Cheng S, Qin J, Qian X, Wang Y*, Li J*, He F*, Xiao T*, Tan M*.Integrative proteomic characterization of human lung adenocarcinoma. Cell.2020, 182(1):245-261.

2.      Zhai L#，Jia X#，Chen Y#，Liu M#，Zhang J#，Ma S，Wang X，Cheng W，He J，Zhou J，Zuo L，Zhang M，Yuan Q，Xu M，Ji J，Tan M*，Liu B*. Comprehensive multi-omicsanalysis elucidates colchicine-induced toxicity mechanisms and unveils thetherapeutic potential of MLN4924 and kinase inhibitors. Acta Pharmacol Sin.2025,46(3):702-714.

3.      Hu H #, Hu W#, Guo A#, ZhaiL#, Ma S, Nie H, Zhou B, Liu T, Jia X, Liu X, Yao X, Tan M*, Chen X*.Spatiotemporal and direct capturing global substrates of lysine-modifyingenzymes in living cells. Nat Commun. 2024,15(1):1465.

4.      Gao Y#，Wang M#，Wang L#，Jia X，Hu C，Liu P，Liu B，Tan M，Zhai L*.The Impact of Different Alkylation Quenching Methods on Tryptic Activity andProtein Identification in Proteomics Sample Preparation. J Mass Spectrom. 2025,60(6):e5141.

5.      Hu C#，Fu H#，Wang L，Gao Y，Li R，Li Z，Li S，Xie X，Ren C，Guo F，Tan M，Zhai L*.Comprehensive Optimization of Packing Parameters for Hydraulic-Packed CapillaryColumns. Rapid Commun Mass Spectrom. 2025,39(7): e9966.

6.      Xu Z#, Fan K#, Li H#, WangL#, Zhu W, Zou S, Zhang Y, Liu Y, Wu Z, Gong Q, Tan M, Wang J*, Zhai L*. Theapplication of proteomics and phosphoproteomics to reveal the molecularmechanism of salidroside in ameliorating myocardial hypoxia. Heliyon.2024,10(9):e30433.

7.       Hao B#, Chen K#, Zhai L#, Liu M, Liu B,Tan M*. Substrate and Functional Diversity of Protein Lysine Post-translationalModifications. Genomics, Proteomics & Bioinformatics 2024, 22(1):qzae019.

8.      Liu M#, Zhai L#, Yang Z#,Li S#, Liu T, Chen A, Wang L, Li Y, Li R, Li C, Tan M, Chen* Z, Qian J*.Integrative Proteomic Analysis Reveals the Cytoskeleton Regulation andMitophagy Difference Between Ischemic Cardiomyopathy and DilatedCardiomyopathy. Mol Cell Proteomics. 2023,22(12):100667.

9.      Du S#,*, Zhai L#, Ye S#,Wang L, Liu L, Tan M*. In-depth urinary and exosome proteome profiling analysisidentifies novel biomarkers for diabetic kidney disease. Sci China Life Sci.2023 Nov;66(11):2587-2603.

10.    Zhai L#, Chen K #, Hao B#,Tan M*. Proteomic characterization of post-translational modifications in drugdiscovery. Acta Pharmacol Sin. 2022 Dec;43(12):3112-3129.

11.    Zhai L#, Wang L#, Hu H,Liu Q, Lee S, Tan M*, Zhang Y*. PBC, an easy and efficient strategy for high-throughputprotein C-terminome profilin. Front Cell Dev Biol. 2022,10:995590.

12.     Liu Q#, Zhai L#, Han M#, Shi D#, Sun Z, Peng S, Wang M, Zhang C, Gao J,Yan W, Jiang Q, Chen D, Xu Q*, Tan M*, Sun Y*. SH2 Domain-ContainingPhosphatase 2 Inhibition Attenuates Osteoarthritis by Maintaining Homeostasisof Cartilage Metabolism via the Docking Protein 1/Uridine Phosphorylase1/Uridine Cascade. Arthritis Rheumatol. 2022, 74(3):462-474.